Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Imago BioSciences (IMGO), a clinical-stage biopharmaceutical company, announced that CEO Hugh Young Rienhoff, Jr., MD, will participate in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. Dr. Rienhoff's pre-recorded presentation will be available for on-demand replay starting at 7:00 AM ET on September 12. The webcast can be accessed via the Investor Relations section of the company’s website, with replay available for 90 days. Imago focuses on developing therapies for myeloproliferative neoplasms and has lead candidate Bomedemstat in Phase 2 trials.

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022.

Dr. Rienhoff will participate in a pre-recorded presentation that will be available for on-demand replay beginning 7:00 am Eastern Time / 4:00 am Pacific Time on September 12.

Interested parties can access the pre-recorded webcast of the presentation by visiting the Investor Relations section of the company’s website at ir.imagobio.com. A webcast replay will be available after the conclusion of the event for approximately 90 days.

Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

INVESTORS
Laurence Watts
Gilmartin Group, LLC.
laurence@gilmartinir.com

MEDIA
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com

Source: Imago BioSciences

FAQ

What is the significance of the H.C. Wainwright 24th Annual Global Investment Conference for IMGO?

The conference provides a platform for Imago BioSciences' CEO to present the company's clinical developments and engage with investors.

When will the presentation by IMGO's CEO be available for on-demand viewing?

The presentation will be available for on-demand replay starting at 7:00 AM ET on September 12, 2022.

What is Bomedemstat and its role in Imago BioSciences' research?

Bomedemstat is Imago's lead product candidate, undergoing Phase 2 clinical trials for treating myeloproliferative neoplasms.

What designations has Bomedemstat received?

Bomedemstat has received U.S. FDA Orphan Drug and Fast Track Designations for treatment of essential thrombocythemia and myelofibrosis.

Where can I access the webcast of Imago BioSciences' presentation?

The webcast can be accessed through the Investor Relations section of Imago's website.